Breaking News Instant updates and real-time market news.

PFE

Pfizer

$36.58

0.37 (1.02%)

, CLLS

Cellectis

$24.02

-1.11 (-4.42%)

18:44
12/12/17
12/12
18:44
12/12/17
18:44

Pfizer's, Servier's UCART19 candidate shows high complete remission rate

Servier, Pfizer (PFE) and Cellectis (CLLS) presented at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta preliminary results from two phase 1 studies of UCART19, an investigational allogeneic anti-CD19 CAR T-cell product, in adult and pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia. These first-in-human data demonstrated the safety and tolerability of UCART19, resulting in an 83% complete remission rate across the adult and pediatric patient population. The CALM study (UCART19 in Advanced Lymphoid Malignancies) is an open label, dose-escalation study designed to evaluate the safety, tolerability and anti-leukemic activity of UCART19 in adult patients with R/R B-ALL. Five out seven patients treated achieved molecular remission at Day 28 post UCAR19. Molecular remission is defined by negative minimal residual disease. MRD is a measurement of the number of residual leukemic cells that remain after treatment. "These early results for UCART19 are very encouraging both in terms of manageable safety and the impressive complete molecular remission rate in these hard-to-treat adult patients with R/R B-ALL," said Reuben Benjamin, Principal Investigator of the CALM Study and Consultant Hematologist at King's College Hospital, United Kingdom. "This first cohort explored a lower dose of UCART19 that is approximately one tenth of that used in most autologous CAR-T trials. These results support additional evaluation of UCART19 at varying doses."

PFE

Pfizer

$36.58

0.37 (1.02%)

CLLS

Cellectis

$24.02

-1.11 (-4.42%)

  • 04

    Jan

PFE Pfizer
$36.58

0.37 (1.02%)

11/13/17
PIPR
11/13/17
NO CHANGE
Target $54
PIPR
Overweight
Pfizer still most compelling risk/reward in global pharma, says Piper Jaffray
Piper Jaffray analyst Richard Purkis says Pfizer remains the most compelling long-run risk/reward opportunity in his global pharma coverage universe. He believes the company's key growth assets, or Ibrance, Eliquis, Xtandi, Xeljanz and Bosulif, and pipeline are being underestimated by investors. Pfizer remains one of the analyst's top 2017 picks. Purkis reiterates an Overweight rating on the shares with a $54 price target.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/14/17
WELS
11/14/17
NO CHANGE
Target $12
WELS
Outperform
Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo
Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
CLLS Cellectis
$24.02

-1.11 (-4.42%)

09/05/17
JEFF
09/05/17
NO CHANGE
Target $47
JEFF
Buy
Jefferies notes UCART123 not included in Cellectis valuation
After the FDA placed clinical holds on both of its trials, Jefferies analyst Biren Amin notes that UCART123 is not in his valuation for Cellectis. The analyst has a Buy rating on the shares with a $47 price target. The company may need to reevaluate the timing of steroid administration and be more aggressive in treating cytokine release syndrome, Amin tells investors in a research note. He's looking for more information and data on the situation.
09/05/17
RHCO
09/05/17
DOWNGRADE
RHCO
Hold
Cellectis downgraded to Hold from Buy at SunTrust
09/05/17
FBCO
09/05/17
NO CHANGE
FBCO
Outperform
No read through to Gilead, Kite from Cellectis clinical hold, says Credit Suisse
Credit Suisse analyst Alethia Young said the safety issues that Cellectis (CLLS) is encountering, and which prompted a clinical hold be placed on the company's allogenic CAR-T drug, UCART123, could be to some degree related to the company's platform. She adds that CRS, which led to a death in Cellectis' BPDCN study, is a known issue with CAR-T technologies and cases have been seen in Juno (JUNO) and Kite's (KITE) programs as well. The analyst, who doesn't think there is a read through to Kite and Gilead (GILD) from the Cellectis news and remains confident Kite will receive approval later this fall and launch Axi-Cel, keeps an Outpeform rating on Gilead shares.
09/06/17
RHCO
09/06/17
DOWNGRADE
RHCO
Hold
Cellectis downgraded on patient death, study halt at SunTrust
As noted earlier, SunTrust downgraded Cellectis to Hold from Buy. Analyst Peter Lawson downgraded the stock after a patient died during the company's BPDCN study, leading the FDA to place a clinical hold on both Phase 1 studies of Cellectis' UCART123, a CAR-T drug. Target to $20 from $35.

TODAY'S FREE FLY STORIES

SSW

Seaspan

$7.28

-0.001 (-0.01%)

10:48
01/16/18
01/16
10:48
01/16/18
10:48
Conference/Events
Seaspan management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

C

Citi

$77.37

0.53 (0.69%)

10:48
01/16/18
01/16
10:48
01/16/18
10:48
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi sees cards revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

SPCB

SuperCom

$3.66

-0.03 (-0.81%)

10:47
01/16/18
01/16
10:47
01/16/18
10:47
Conference/Events
SuperCom management to meet with Drexel Hamilton »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

EIGR

Eiger BioPharmaceuticals

$16.00

0.65 (4.23%)

10:46
01/16/18
01/16
10:46
01/16/18
10:46
Recommendations
Eiger BioPharmaceuticals analyst commentary  »

Eiger BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

  • 26

    Feb

  • 08

    Apr

KBH

KB Home

$36.03

-0.95 (-2.57%)

10:46
01/16/18
01/16
10:46
01/16/18
10:46
Conference/Events
KB Home management to meet with JMP Securities »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

JKHY

Jack Henry

$123.38

0.7 (0.57%)

10:45
01/16/18
01/16
10:45
01/16/18
10:45
Conference/Events
Jack Henry management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

10:45
01/16/18
01/16
10:45
01/16/18
10:45
Conference/Events
Wolfe Research utilities analyst to hold a luncheon meeting »

Senior Utilities Analyst…

ECL

Ecolab

$137.42

-0.26 (-0.19%)

10:44
01/16/18
01/16
10:44
01/16/18
10:44
Conference/Events
Ecolab management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 20

    Feb

CXP

Columbia Property

$21.93

0.08 (0.37%)

10:43
01/16/18
01/16
10:43
01/16/18
10:43
Conference/Events
Columbia Property management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 15

    Feb

TWTR

Twitter

$24.96

-0.45 (-1.77%)

, FB

Facebook

$179.37

-8.4 (-4.47%)

10:43
01/16/18
01/16
10:43
01/16/18
10:43
Hot Stocks
Former bear says buy Twitter as growth returns, takeover potential rises »

Aegis analyst Victor…

TWTR

Twitter

$24.96

-0.45 (-1.77%)

FB

Facebook

$179.37

-8.4 (-4.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 08

    Feb

FB

Facebook

$179.37

-8.4 (-4.47%)

, SNAP

Snap

$13.53

-0.585 (-4.15%)

10:41
01/16/18
01/16
10:41
01/16/18
10:41
Conference/Events
FBN Securities media analysts to hold a group luncheon »

Analysts host a Group…

FB

Facebook

$179.37

-8.4 (-4.47%)

SNAP

Snap

$13.53

-0.585 (-4.15%)

TWTR

Twitter

$24.96

-0.455 (-1.79%)

GOOG

Alphabet

$1,122.26

16.74 (1.51%)

GOOGL

Alphabet Class A

$1,130.65

18.6 (1.67%)

LNKD

Acquired by MSFT

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 18

    Mar

GE

General Electric

$18.14

-0.625 (-3.33%)

10:40
01/16/18
01/16
10:40
01/16/18
10:40
Periodicals
GE seen as likely to embrace company breakup, CNBC reports »

General Electric is seen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

HMNY

Helios and Matheson

$7.64

-0.42 (-5.21%)

10:40
01/16/18
01/16
10:40
01/16/18
10:40
Hot Stocks
MoviePass names Natasha Mulla CMO »

MoviePass, movie-theater…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEM

MSCI Emerging Markets Index

$49.79

0.275 (0.56%)

10:40
01/16/18
01/16
10:40
01/16/18
10:40
Options
Notable interest in iShares Emerging Markets Fund options »

Notable interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$77.54

0.695 (0.90%)

10:38
01/16/18
01/16
10:38
01/16/18
10:38
Hot Stocks
Citi CFO says U.S. Retail Services growing slightly above outlook »

CFO John Gerspach said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

VPG

Vishay Precision

$27.30

0.55 (2.06%)

10:38
01/16/18
01/16
10:38
01/16/18
10:38
Conference/Events
Vishay Precision management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 29

    Mar

SITE

SiteOne Landscape

$71.28

-0.2 (-0.28%)

10:37
01/16/18
01/16
10:37
01/16/18
10:37
Conference/Events
SiteOne Landscape management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

IWM

iShares Trust Russell 2000 Index Fund

$159.21

1.05 (0.66%)

, RUT

Russell 2000 Index

10:36
01/16/18
01/16
10:36
01/16/18
10:36
Technical Analysis
Technical View: Russell 2000 Index crosses above 1600, new life high »

The Russell 2000 (RUT)…

IWM

iShares Trust Russell 2000 Index Fund

$159.21

1.05 (0.66%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTH

LightPath

$2.42

0.09 (3.86%)

10:36
01/16/18
01/16
10:36
01/16/18
10:36
Conference/Events
LightPath management to meet with Roth Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

LOW

Lowe's

$104.00

3.14 (3.11%)

10:35
01/16/18
01/16
10:35
01/16/18
10:35
Conference/Events
Lowe's management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

GE

General Electric

$18.17

-0.595 (-3.17%)

10:35
01/16/18
01/16
10:35
01/16/18
10:35
Periodicals
GE breakup likely, announcement may come this Spring, CNBC reports »

CNBC's David Faber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

C

Citi

$77.56

0.715 (0.93%)

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi CFO: Trading-related…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Conference/Events
UBS leisure analyst holds an analyst/industry conference call »

Leisure Analyst Farley…

ITRN

Ituran

$35.30

1.25 (3.67%)

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Conference/Events
Ituran management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 17

    Jan

C

Citi

$77.50

0.66 (0.86%)

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi sees core accrual…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.